Human monogenetic diseases can arise from the aberrant expansion of tandem nucleotide repeat sequences, which when transcribed into RNA, can misfold and aggregate into toxic nuclear foci 1 . Nuclear retention of repeat-containing RNAs can disrupt their normal expression and induce widespread splicing defects by sequestering essential RNA binding proteins. Among the most prevalent of these disorders is myotonic dystrophy type 1 (DM1), a disease occurring from the expression of a noncoding CTG repeat expansion in the 3'UTR of the human dystrophia myotonica protein kinase (DMPK) gene 2,3 . Here we show that RNAbinding CRISPR-Cas13, with a robust non-classical nuclear localization signal, can be efficiently targeted to toxic nuclear RNA foci for either visualization or cleavage, tools we named hilightR and eraseR, respectively. HilightR combines catalytically dead Cas13b (dCas13b) with a fluorescent protein to directly visualize CUG repeat RNA foci in the nucleus of live cells, allowing for quantification of foci number and observation of foci dynamics. EraseR utilizes the intrinsic endoribonuclease activity of Cas13b, targeted to nuclear CUG repeat RNA, to disrupt nuclear foci. These studies demonstrate the potential for targeting toxic nuclear RNA foci directly with CRISPR-Cas13 for either the identification or treatment of DM1. The efficient and sequence programmable nature of CRISPR-Cas13 systems will allow for rapid targeting and manipulation of other human nuclear RNA disorders, without the associated risks of genome editing.
dystrophy, occurring in roughly 1 in 8,000 individuals 5 . Mutant DMPK mRNAs with greater than ~50 CUG repeats form toxic nuclear RNA foci, which prevent normal DMPK expression and induce widespread defects in alternative splicing and polyadenylation by sequestering members of the muscleblind-like (MBNL) family of RNA binding proteins [6] [7] [8] [9] [10] [11] [12] [13] . Loss of MBNL1 and 2 function account for up to 80% of the observed DM1 phenotype, however, overexpression of MBNL proteins have had limited success rescuing splicing defects and only modest amelioration of muscle function in DM1 mouse models, suggesting a multifactorial cause for DM1 symptoms [14] [15] [16] [17] . The multitude of dysfunctional pathologies associated with the formation of toxic RNA foci suggests that targeted degradation of CUG expansion (CUG exp ) RNA would provide therapeutic benefit to DM1 patients.
Despite intense effort, there are no currently approved therapies designed to treat DM1. Antisense oligonucleotides (ASOs) targeting CUG-repeats have been successfully used to reduce the levels of toxic RNAs and disrupt binding and sequestration of MBNL proteins in animal models 18, 19 . However, significant challenges remain for the delivery of these molecules at therapeutically effective levels in human skeletal muscle. Genome editing approaches using CRISPR-Cas9 DNA endonucleases have been employed to directly edit the DMPK gene locus. However, CRISPR-Cas9 editing at either the 5' or 3' ends of CTG genomic repeats can induce large and uncontrolled sequence deletions, and the use of double guide-RNAs flanking the repeat expansion can lead to frequent sequence inversions, which remain toxic 20, 21 . Since CRISPR-Cas9 approaches for manipulating DNA remain inefficient and controversial due to the risk of germline editing, an alternative approach targeting the repeat RNAs using deactivated Cas9 (dCas9) fused to an active ribonuclease has recently been shown to be effective in cells 22 . However, the efficiency of this approach for targeting nuclear CUG exp RNA in DM1 patients could be limited by a number of factors, such as: 1) dCas9 retains affinity for DNA, which could compete for its binding to RNA, 2) the large size of dCas9 fusion proteins may limit their nuclear localization or delivery in vivo, 3) dCas9 utilizes short guide-RNAs which may increase the chance of off-target RNA cleavage and, 4) they require protospacer adjacent motifs (PAM) for efficient binding, which are not present in most human repeat expansion sequences. Thus, significant challenges remain for the development of efficient therapeutic strategies to target toxic nuclear RNAs in DM1 patients.
In contrast, bacterial-derived CRISPR-Cas13 systems bind specifically to RNA and function as endoribonucleases to cleave RNA, bypassing the risk of germline editing that is associated with DNA-binding CRISPR-Cas endonucleases [23] [24] [25] . Single residue mutations within the two nuclease domains of Cas13 generate a catalytically deactivated enzyme (dCas13), which retains programmable RNA binding affinity in mammalian systems without the requirement for PAM sequences for efficient targeting 26 . Due to their large size and lack of intrinsic localization signals, both Cas9 and Cas13 fusion proteins are inefficiently localized to the mammalian nucleus. In our recent pre-print manuscript describing the adaptation of CRISPR-Cas13 for inducing targeted RNA cleavage and polyadenylation (https://doi.org/10.1101/531111), we identified a non-classical nuclear localization signal (NLS) derived from the yeast Ty1 retrotransposon which promotes robust nuclear localization of Cas13. The powerful activity of the Ty1 NLS suggested that efficient targeting of nuclear RNAs could be achieved for either visualization or cleavage using CRISPR-Cas13.
To visualize nuclear RNAs using CRISPR-Cas13, we designed a fusion protein combining the catalytically dead Type VI-B Cas13b enzyme from Prevotella sp. P5-125 (dPspCas13b) with either a C-terminal enhanced Green Fluorescent Protein (eGFP) or red fluorescent protein, mCherry ( Figure 1A) . A 3x FLAG epitope tag (F) and Ty1 nuclear localization sequence (Ty1 NLS) were added to the N-terminus of the dPspCas13b fusion proteins to promote efficient nuclear localization, hereinafter referred to as hilightR green or hilightR red ( Figure 1A ). Toxic RNA foci are the cellular hallmark of DM1 and can be induced in many cell types by the expression of transgenes expressing expanded CUG repeats. To mimic the nuclear RNA foci found in patients with DM1, we utilized a vector containing 960 CUG repeats in the human DMPK 3' UTR (DT960) ( Figure   1B ) 27 . The DT960 construct is sufficient to recapitulate RNA foci formation in cells and can be detected by Fluorescent In Situ Hybridization (FISH) using an antisense (CAG) repeat probe or with an mCherry-MBNL1 fusion protein ( Supplementary Figures 1A and   B ). To target hilightR fusion proteins to CUG repeats, we designed a PspCas13bcompatible crRNA containing an antisense CAG repeat target sequence (CAGx9), which is predicted to hybridize with 9 CUG repeats ( Figure 1C ). Guided by the CAGx9 repeat crRNA, hilightR green and red were completely nuclear localized and highlighted nuclear RNA foci generated by the DT960 vector ( Figure 1D and Supplementary Figure 1C ). In contrast, co-expression of hilightR constructs with a non-targeting crRNA resulted in broad, un-localized nuclear fluorescence ( Figure 1D and Supplementary Figure 1C ).
Nuclear foci labeled with hilightR green co-localized with an Alexa Fluor 488conjugated CAG oligonucleotide probe (AF488-CAGx7), detected using FISH ( Figure   2A ). Consistent with previous reports, nuclear foci labeled with hilightR green co-localized with MBNL1 protein, detected using an mCherry-MBNL1 fusion protein, and partially colocalized with splicing speckles, detected with an antibody specific for SC-35 ( Figure 2B and Supplementary Figure 2 ). These results demonstrate that hilightR accurately targets CUG exp RNA foci.
The efficient nuclear targeting of CRISPR-Cas13 to CUG exp RNA foci suggested it could be a useful for targeted cleavage of toxic CUG exp RNA, using its inherent endoribonuclease activity. Cas13 has been shown to be useful for specific cleavage of mRNA transcripts in mammalian and plant cells 26, 28, 29 . To determine if Cas13 endoribonuclease activity is sufficient to cleave CUG exp RNA foci, we modified the hilightR green fusion protein by reactivating PspCas13b's catalytic mutations using site directed mutagenesis. Surprisingly, we found that activated hilightR green did not significantly reduce the number of RNA foci using the CAGx9 targeting crRNA, compared with a nontargeting guide-RNA (data not shown). However, activated PspCas13b containing the Nterminal Ty1 NLS, but lacking the C-terminal eGFP (herein referred to as eraseR), resulted in a significant reduction in the number and intensity of RNA foci, quantified using an mCherry-MBNL1 fusion protein ( Figure 3A and B). Since target site flanking sequences can influence Cas13 nuclease activation, we tested CAGx9 crRNAs in two other reading frames (CAGx9-f2 and CAGx9-f3). EraseR guided by all three CAGx9 crRNAs resulted in significant reduction in the number and intensity of RNA foci per cell, compared to a non-targeting crRNA ( Figure 3A Figure 3 ). These date demonstrate for the first time that CRISPR-Cas13 is sufficient to degrade CUG exp RNA foci.
While there are currently no available treatments for myotonic dystrophies or other human RNA repeat expansion disorders, the rapid development of CRISPR-Cas13 systems offer hope that targeted approaches to treat DM1 will soon be achievable. We have shown that Cas13b, localized by a powerful non-classical Ty1 NLS, can be used to efficiently target nuclear CUG exp RNA foci for either visualization or targeted degradation in mammalian cells. The NLS used in these studies was derived from the yeast Ty1 LTRretrotransposon (Ty1 NLS), which replicates its genome through a cytoplasmic intermediate 30 . As opposed to higher eukaryotes in which the nuclear envelope breaks down during cell division, the nuclear envelope in yeast remains intact during cell division and thus Ty1 requires active nuclear import for retrotransposition 31 . Interestingly, quiescent mammalian cells also retain a nuclear envelope, suggesting that the Ty1 NLS may be useful for targeting nuclear RNAs by Cas proteins in non-dividing cells.
The programmable nature of CRISPR-Cas13, through simple modification of crRNA target sequences, allow hilightR and eraseR to be easily adapted for the study and cleavage of other nuclear RNAs, or other repeat expansion disorders such as myotonic dystrophy type 2 (DM2), amyotrophic lateral sclerosis (ALS), huntington's disease-like 2 (HDL2), spinocerebellar ataxias 8, 31 and 10 (SCA8, -31, -10) and fragile X-associated tremor ataxia syndrome (FXTAS). As with other approaches (ASOs or CRISPR-Cas) targeted to simple repeat sequences, there remains the potential for 'coincidental' cleavage of other human mRNA transcripts which contain these short repeat sequence motifs. Future studies will be necessary to evaluate any potential deleterious impacts resulting from coincidental cleavage events. Alternatively, directly targeting unique human DMPK transcript sequences for degradation by CRISPR-Cas13 or by other forms of RNA manipulation may offer additional approaches for the treatment of toxic RNA diseases. 
METHODS

Synthetic DNA and Cloning
The mammalian expression vector containing an N-terminal 3x FLAG and Ty1 NLS fused to dPspCas13b (described previously, https://doi.org/10.1101/531111) was modified to encode a C-terminal enhanced Green Fluorescent Protein (eGFP) or red fluorescent protein, mCherry. All crRNAs were designed to be 30 nucleotides in length and start with a 5' G for efficient transcription from the hU6 promoter in pC00043 26 . The negative control non-targeting crRNA has been previous described 26 ATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATG  ACAAGGGCGGAAACTCAAAGAAAAGGTCACTGGAGGACAACGAAACGGAAATCAAAGTCTCCAG  AGACACCTGGAACACTAAGAACATGCGGTCCCTGGAACCGCCACGAAGCAAGAAACGGATACAT  GGAGGCAACATCCCCGCTCTGGTGGAAAACCAGAAGAAGTACTTTGGCACCTACAGCGTGATGG  CCATGCTGAACGCTCAGACCGTGCTGGACCACATCCAGAAGGTGGCCGATATTGAGGGCGAGCA  GAACGAGAACAACGAGAATCTGTGGTTTCACCCCGTGATGAGCCACCTGTACAACGCCAAGAAC  GGCTACGACAAGCAGCCCGAGAAAACCATGTTCATCATCGAGCGGCTGCAGAGCTACTTCCCAT  TCCTGAAGATCATGGCCGAGAACCAGAGAGAGTACAGCAACGGCAAGTACAAGCAGAACCGCGT  GGAAGTGAACAGCAACGACATCTTCGAGGTGCTGAAGCGCGCCTTCGGCGTGCTGAAGATGTAC  AGGGACCTGACCAACGCATACAAGACCTACGAGGAAAAGCTGAACGACGGCTGCGAGTTCCTGA  CCAGCACAGAGCAACCTCTGAGCGGCATGATCAACAACTACTACACAGTGGCCCTGCGGAACAT  GAACGAGAGATACGGCTACAAGACAGAGGACCTGGCCTTCATCCAGGACAAGCGGTTCAAGTTC  GTGAAGGACGCCTACGGCAAGAAAAAGTCCCAAGTGAATACCGGATTCTTCCTGAGCCTGCAGG  ACTACAACGGCGACACACAGAAGAAGCTGCACCTGAGCGGAGTGGGAATCGCCCTGCTGATCTG  CCTGTTCCTGGACAAGCAGTACATCAACATCTTTCTGAGCAGGCTGCCCATCTTCTCCAGCTAC  AATGCCCAGAGCGAGGAACGGCGGATCATCATCAGATCCTTCGGCATCAACAGCATCAAGCTGC  CCAAGGACCGGATCCACAGCGAGAAGTCCAACAAGAGCGTGGCCATGGATATGCTCAACGAAGT  GAAGCGGTGCCCCGACGAGCTGTTCACAACACTGTCTGCCGAGAAGCAGTCCCGGTTCAGAATC  ATCAGCGACGACCACAATGAAGTGCTGATGAAGCGGAGCAGCGACAGATTCGTGCCTCTGCTGC  TGCAGTATATCGATTACGGCAAGCTGTTCGACCACATCAGGTTCCACGTGAACATGGGCAAGCT  GAGATACCTGCTGAAGGCCGACAAGACCTGCATCGACGGCCAGACCAGAGTCAGAGTGATCGAG  CAGCCCCTGAACGGCTTCGGCAGACTGGAAGAGGCCGAGACAATGCGGAAGCAAGAGAACGGCA  CCTTCGGCAACAGCGGCATCCGGATCAGAGACTTCGAGAACATGAAGCGGGACGACGCCAATCC  TGCCAACTATCCCTACATCGTGGACACCTACACACACTACATCCTGGAAAACAACAAGGTCGAG  ATGTTTATCAACGACAAAGAGGACAGCGCCCCACTGCTGCCCGTGATCGAGGATGATAGATACG  TGGTCAAGACAATCCCCAGCTGCCGGATGAGCACCCTGGAAATTCCAGCCATGGCCTTCCACAT  GTTTCTGTTCGGCAGCAAGAAAACCGAGAAGCTGATCGTGGACGTGCACAACCGGTACAAGAGA  CTGTTCCAGGCCATGCAGAAAGAAGAAGTGACCGCCGAGAATATCGCCAGCTTCGGAATCGCCG  AGAGCGACCTGCCTCAGAAGATCCTGGATCTGATCAGCGGCAATGCCCACGGCAAGGATGTGGA  CGCCTTCATCAGACTGACCGTGGACGACATGCTGACCGACACCGAGCGGAGAATCAAGAGATTC  AAGGACGACCGGAAGTCCATTCGGAGCGCCGACAACAAGATGGGAAAGAGAGGCTTCAAGCAGA  TCTCCACAGGCAAGCTGGCCGACTTCCTGGCCAAGGACATCGTGCTGTTTCAGCCCAGCGTGAA  CGATGGCGAGAACAAGATCACCGGCCTGAACTACCGGATCATGCAGAGCGCCATTGCCGTGTAC  GATAGCGGCGACGATTACGAGGCCAAGCAGCAGTTCAAGCTGATGTTCGAGAAGGCCCGGCTGA  TCGGCAAGGGCACAACAGAGCCTCATCCATTTCTGTACAAGGTGTTCGCCCGCAGCATCCCCGC  CAATGCCGTCGAGTTCTACGAGCGCTACCTGATCGAGCGGAAGTTCTACCTGACCGGCCTGTCC  AACGAGATCAAGAAAGGCAACAGAGTGGATGTGCCCTTCATCCGGCGGGACCAGAACAAGTGGA  AAACACCCGCCATGAAGACCCTGGGCAGAATCTACAGCGAGGATCTGCCCGTGGAACTGCCCAG  ACAGATGTTCGACAATGAGATCAAGTCCCACCTGAAGTCCCTGCCACAGATGGAAGGCATCGAC  TTCAACAATGCCAACGTGACCTATCTGATCGCCGAGTACATGAAGAGAGTGCTGGACGACGACT  TCCAGACCTTCTACCAGTGGAACCGCAACTACCGGTACATGGACATGCTTAAGGGCGAGTACGA  CAGAAAGGGCTCCCTGCAGCACTGCTTCACCAGCGTGGAAGAGAGAGAAGGCCTCTGGAAAGAG  CGGGCCTCCAGAACAGAGCGGTACAGAAAGCAGGCCAGCAACAAGATCCGCAGCAACCGGCAGA  TGAGAAACGCCAGCAGCGAAGAGATCGAGACAATCCTGGATAAGCGGCTGAGCAACAGCCGGAA  CGAGTACCAGAAAAGCGAGAAAGTGATCCGGCGCTACAGAGTGCAGGATGCCCTGCTGTTTCTG  CTGGCCAAAAAGACCCTGACCGAACTGGCCGATTTCGACGGCGAGAGGTTCAAACTGAAAGAAA  TCATGCCCGACGCCGAGAAGGGAATCCTGAGCGAGATCATGCCCATGAGCTTCACCTTCGAGAA  AGGCGGCAAGAAGTACACCATCACCAGCGAGGGCATGAAGCTGAAGAACTACGGCGACTTCTTT  GTGCTGGCTAGCGACAAGAGGATCGGCAACCTGCTGGAACTCGTGGGCAGCGACATCGTGTCCA  AAGAGGATATCATGGAAGAGTTCAACAAATACGACCAGTGCAGGCCCGAGATCAGCTCCATCGT  GTTCAACCTGGAAAAGTGGGCCTTCGACACATACCCCGAGCTGTCTGCCAGAGTGGACCGGGAA  GAGAAGGTGGACTTCAAGAGCATCCTGAAAATCCTGCTGAACAACAAGAACATCAACAAAGAGC  AGAGCGACATCCTGCGGAAGATCCGGAACGCCTTCGATGCAAACAATTACCCCGACAAAGGCGT  GGTGGAAATCAAGGCCCTGCCTGAGATCGCCATGAGCATCAAGAAGGCCTTTGGGGAGTACGCC  ATCATGAAGTCGCGAGGCGGTGGAGGTAGTGGAGGGGGAGGATCAACGCGTGTGAGCAAGGGCG  AGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAA  GTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATC  TGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGC  AGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGA  AGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAG  GTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGG  ACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGC  CGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGC  GTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCG  ACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACAT  GGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG ATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATG  ACAAGGGCGGAAACTCAAAGAAAAGGTCACTGGAGGACAACGAAACGGAAATCAAAGTCTCCAG  AGACACCTGGAACACTAAGAACATGCGGTCCCTGGAACCGCCACGAAGCAAGAAACGGATACAT  GGAGGCAACATCCCCGCTCTGGTGGAAAACCAGAAGAAGTACTTTGGCACCTACAGCGTGATGG  CCATGCTGAACGCTCAGACCGTGCTGGACCACATCCAGAAGGTGGCCGATATTGAGGGCGAGCA  GAACGAGAACAACGAGAATCTGTGGTTTCACCCCGTGATGAGCCACCTGTACAACGCCAAGAAC  GGCTACGACAAGCAGCCCGAGAAAACCATGTTCATCATCGAGCGGCTGCAGAGCTACTTCCCAT  TCCTGAAGATCATGGCCGAGAACCAGAGAGAGTACAGCAACGGCAAGTACAAGCAGAACCGCGT  GGAAGTGAACAGCAACGACATCTTCGAGGTGCTGAAGCGCGCCTTCGGCGTGCTGAAGATGTAC  AGGGACCTGACCAACGCATACAAGACCTACGAGGAAAAGCTGAACGACGGCTGCGAGTTCCTGA  CCAGCACAGAGCAACCTCTGAGCGGCATGATCAACAACTACTACACAGTGGCCCTGCGGAACAT  GAACGAGAGATACGGCTACAAGACAGAGGACCTGGCCTTCATCCAGGACAAGCGGTTCAAGTTC  GTGAAGGACGCCTACGGCAAGAAAAAGTCCCAAGTGAATACCGGATTCTTCCTGAGCCTGCAGG  ACTACAACGGCGACACACAGAAGAAGCTGCACCTGAGCGGAGTGGGAATCGCCCTGCTGATCTG  CCTGTTCCTGGACAAGCAGTACATCAACATCTTTCTGAGCAGGCTGCCCATCTTCTCCAGCTAC  AATGCCCAGAGCGAGGAACGGCGGATCATCATCAGATCCTTCGGCATCAACAGCATCAAGCTGC  CCAAGGACCGGATCCACAGCGAGAAGTCCAACAAGAGCGTGGCCATGGATATGCTCAACGAAGT  GAAGCGGTGCCCCGACGAGCTGTTCACAACACTGTCTGCCGAGAAGCAGTCCCGGTTCAGAATC  ATCAGCGACGACCACAATGAAGTGCTGATGAAGCGGAGCAGCGACAGATTCGTGCCTCTGCTGC  TGCAGTATATCGATTACGGCAAGCTGTTCGACCACATCAGGTTCCACGTGAACATGGGCAAGCT  GAGATACCTGCTGAAGGCCGACAAGACCTGCATCGACGGCCAGACCAGAGTCAGAGTGATCGAG  CAGCCCCTGAACGGCTTCGGCAGACTGGAAGAGGCCGAGACAATGCGGAAGCAAGAGAACGGCA  CCTTCGGCAACAGCGGCATCCGGATCAGAGACTTCGAGAACATGAAGCGGGACGACGCCAATCC  TGCCAACTATCCCTACATCGTGGACACCTACACACACTACATCCTGGAAAACAACAAGGTCGAG  ATGTTTATCAACGACAAAGAGGACAGCGCCCCACTGCTGCCCGTGATCGAGGATGATAGATACG  TGGTCAAGACAATCCCCAGCTGCCGGATGAGCACCCTGGAAATTCCAGCCATGGCCTTCCACAT  GTTTCTGTTCGGCAGCAAGAAAACCGAGAAGCTGATCGTGGACGTGCACAACCGGTACAAGAGA  CTGTTCCAGGCCATGCAGAAAGAAGAAGTGACCGCCGAGAATATCGCCAGCTTCGGAATCGCCG  AGAGCGACCTGCCTCAGAAGATCCTGGATCTGATCAGCGGCAATGCCCACGGCAAGGATGTGGA  CGCCTTCATCAGACTGACCGTGGACGACATGCTGACCGACACCGAGCGGAGAATCAAGAGATTC  AAGGACGACCGGAAGTCCATTCGGAGCGCCGACAACAAGATGGGAAAGAGAGGCTTCAAGCAGA  TCTCCACAGGCAAGCTGGCCGACTTCCTGGCCAAGGACATCGTGCTGTTTCAGCCCAGCGTGAA  CGATGGCGAGAACAAGATCACCGGCCTGAACTACCGGATCATGCAGAGCGCCATTGCCGTGTAC  GATAGCGGCGACGATTACGAGGCCAAGCAGCAGTTCAAGCTGATGTTCGAGAAGGCCCGGCTGA  TCGGCAAGGGCACAACAGAGCCTCATCCATTTCTGTACAAGGTGTTCGCCCGCAGCATCCCCGC  CAATGCCGTCGAGTTCTACGAGCGCTACCTGATCGAGCGGAAGTTCTACCTGACCGGCCTGTCC  AACGAGATCAAGAAAGGCAACAGAGTGGATGTGCCCTTCATCCGGCGGGACCAGAACAAGTGGA  AAACACCCGCCATGAAGACCCTGGGCAGAATCTACAGCGAGGATCTGCCCGTGGAACTGCCCAG  ACAGATGTTCGACAATGAGATCAAGTCCCACCTGAAGTCCCTGCCACAGATGGAAGGCATCGAC  TTCAACAATGCCAACGTGACCTATCTGATCGCCGAGTACATGAAGAGAGTGCTGGACGACGACT  TCCAGACCTTCTACCAGTGGAACCGCAACTACCGGTACATGGACATGCTTAAGGGCGAGTACGA  CAGAAAGGGCTCCCTGCAGCACTGCTTCACCAGCGTGGAAGAGAGAGAAGGCCTCTGGAAAGAG  CGGGCCTCCAGAACAGAGCGGTACAGAAAGCAGGCCAGCAACAAGATCCGCAGCAACCGGCAGA  TGAGAAACGCCAGCAGCGAAGAGATCGAGACAATCCTGGATAAGCGGCTGAGCAACAGCCGGAA  CGAGTACCAGAAAAGCGAGAAAGTGATCCGGCGCTACAGAGTGCAGGATGCCCTGCTGTTTCTG  CTGGCCAAAAAGACCCTGACCGAACTGGCCGATTTCGACGGCGAGAGGTTCAAACTGAAAGAAA  TCATGCCCGACGCCGAGAAGGGAATCCTGAGCGAGATCATGCCCATGAGCTTCACCTTCGAGAA  AGGCGGCAAGAAGTACACCATCACCAGCGAGGGCATGAAGCTGAAGAACTACGGCGACTTCTTT  GTGCTGGCTAGCGACAAGAGGATCGGCAACCTGCTGGAACTCGTGGGCAGCGACATCGTGTCCA  AAGAGGATATCATGGAAGAGTTCAACAAATACGACCAGTGCAGGCCCGAGATCAGCTCCATCGT  GTTCAACCTGGAAAAGTGGGCCTTCGACACATACCCCGAGCTGTCTGCCAGAGTGGACCGGGAA  GAGAAGGTGGACTTCAAGAGCATCCTGAAAATCCTGCTGAACAACAAGAACATCAACAAAGAGC  AGAGCGACATCCTGCGGAAGATCCGGAACGCCTTCGATGCAAACAATTACCCCGACAAAGGCGT  GGTGGAAATCAAGGCCCTGCCTGAGATCGCCATGAGCATCAAGAAGGCCTTTGGGGAGTACGCC  ATCATGAAGTCGCGAGGCGGTGGAGGTAGTGGAGGGGGAGGATCAACGCGTGTGAGCAAGGGCG  AGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAGGGCTCCGT  GAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACC  GCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGT  TCATGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCGACTACTTGAAGCTGTC  CTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTG  ACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACT  TCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGAT  GTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGC  CACTACGACGCTGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCT  ACAACGTCAACATCAAGTTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTA CCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGCAGAGGCTGAA  GCTGAAGGACGGCGGCCACTACGACGCTGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTG  CAGCTGCCCGGCGCCTACAACGTCAACATCAAGTTGGACATCACCTCCCACAACGAGGACTACA  CCATCGTGGAACAGTACGAACGCGCCGAGGGCCGCCACTCCACCGGCGGCATGGACGAGCTGTA  CAAGGGGAATTCAAGGCCTCTCGAGGCAGTCTCTGTAACACCAATTAGGGATACCAAATGGCTG  ACGCTGGAGGTATGCCGAGAGTTTCAACGCGGAACCTGTAGTCGCCCTGATACGGAGTGCAAGT  TTGCCCACCCCTCTAAGTCTTGCCAAGTAGAGAATGGGAGAGTCATCGCTTGCTTCGACAGTCT  TAAAGGCCGATGTTCACGGGAAAACTGCAAATATCTTCACCCGCCGCCACATCTCAAAACTCAG  CTTGAGATCAACGGTCGGAACAACCTTATCCAACAGAAAAATATGGCTATGTTGGCGCAGCAGA  TGCAGCTTGCAAATGCTATGATGCCCGGTGCACCTTTGCAACCGGTTCCAATGTTCTCAGTGGC  TCCATCCCTCGCAACAAATGCCTCCGCAGCGGCTTTTAACCCGTACCTCGGCCCCGTATCCCCA  TCCCTTGTGCCCGCGGAGATACTTCCGACGGCACCCATGTTGGTTACAGGCAATCCAGGGGTAC  CCGTACCCGCGGCAGCGGCCGCTGCGGCGCAAAAACTTATGCGGACAGATCGGCTCGAAGTCTG  TAGAGAATATCAAAGGGGTAACTGTAACAGGGGGGAAAACGACTGCAGATTCGCTCACCCAGCG  GATAGTACAATGATCGACACGAATGACAACACCGTTACCGTATGCATGGACTACATTAAGGGCC  GCTGCAGCAGAGAGAAGTGCAAATACTTTCACCCACCCGCCCATCTGCAAGCCAAAATCAAGGC  GGCTCAATACCAAGTCAATCAAGCGGCGGCCGCTCAAGCCGCAGCCACTGCGGCAGCAATGGGT  ATCCCGCAAGCCGTTCTTCCCCCTCTCCCAAAGCGACCGGCCCTCGAAAAAACCAATGGAGCTA  CCGCCGTCTTCAATACGGGCATCTTCCAGTACCAACAAGCCTTGGCTAATATGCAACTTCAACA  ACACACAGCGTTCTTGCCACCAGGATCTATCCTTTGCATGACGCCAGCCACGAGTGTGGTGCCC  ATGGTTCACGGTGCGACGCCAGCGACTGTATCTGCGGCTACTACGTCCGCAACATCCGTTCCGT  TTGCCGCGACTGCCACGGCAAATCAAATACCGATAATTAGCGCAGAACACTTGACGAGCCACAA  ATACGTCACTCAAATGTAG   mCherry-MBNL1  MVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWD  ILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVK  LRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPV  QLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKGNSRPLEAVSVTPIRDTKWL  TLEVCREFQRGTCSRPDTECKFAHPSKSCQVENGRVIACFDSLKGRCSRENCKYLHPPPHLKTQ  LEINGRNNLIQQKNMAMLAQQMQLANAMMPGAPLQPVPMFSVAPSLATNASAAAFNPYLGPVSP  SLVPAEILPTAPMLVTGNPGVPVPAAAAAAAQKLMRTDRLEVCREYQRGNCNRGENDCRFAHPA  DSTMIDTNDNTVTVCMDYIKGRCSREKCKYFHPPAHLQAKIKAAQYQVNQAAAAQAAATAAAMG  IPQAVLPPLPKRPALEKTNGATAVFNTGIFQYQQALANMQLQQHTAFLPPGSILCMTPATSVVP  MVHGATPATVSAATTSATSVPFAATATANQIPIISAEHLTSHKYVTQM*   eraseR   3xFLAG-Ty1NLS-PspCas13b  ATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATG  ACAAGGGCGGAAACTCAAAGAAAAGGTCACTGGAGGACAACGAAACGGAAATCAAAGTCTCCAG  AGACACCTGGAACACTAAGAACATGCGGTCCCTGGAACCGCCACGAAGCAAGAAACGGATACAT  GGAGGCAACATCCCCGCTCTGGTGGAAAACCAGAAGAAGTACTTTGGCACCTACAGCGTGATGG  CCATGCTGAACGCTCAGACCGTGCTGGACCACATCCAGAAGGTGGCCGATATTGAGGGCGAGCA  GAACGAGAACAACGAGAATCTGTGGTTTCACCCCGTGATGAGCCACCTGTACAACGCCAAGAAC  GGCTACGACAAGCAGCCCGAGAAAACCATGTTCATCATCGAGCGGCTGCAGAGCTACTTCCCAT  TCCTGAAGATCATGGCCGAGAACCAGAGAGAGTACAGCAACGGCAAGTACAAGCAGAACCGCGT  GGAAGTGAACAGCAACGACATCTTCGAGGTGCTGAAGCGCGCCTTCGGCGTGCTGAAGATGTAC  AGGGACCTGACCAACCACTACAAGACCTACGAGGAAAAGCTGAACGACGGCTGCGAGTTCCTGA  CCAGCACAGAGCAACCTCTGAGCGGCATGATCAACAACTACTACACAGTGGCCCTGCGGAACAT  GAACGAGAGATACGGCTACAAGACAGAGGACCTGGCCTTCATCCAGGACAAGCGGTTCAAGTTC  GTGAAGGACGCCTACGGCAAGAAAAAGTCCCAAGTGAATACCGGATTCTTCCTGAGCCTGCAGG  ACTACAACGGCGACACACAGAAGAAGCTGCACCTGAGCGGAGTGGGAATCGCCCTGCTGATCTG  CCTGTTCCTGGACAAGCAGTACATCAACATCTTTCTGAGCAGGCTGCCCATCTTCTCCAGCTAC  AATGCCCAGAGCGAGGAACGGCGGATCATCATCAGATCCTTCGGCATCAACAGCATCAAGCTGC  CCAAGGACCGGATCCACAGCGAGAAGTCCAACAAGAGCGTGGCCATGGATATGCTCAACGAAGT  GAAGCGGTGCCCCGACGAGCTGTTCACAACACTGTCTGCCGAGAAGCAGTCCCGGTTCAGAATC  ATCAGCGACGACCACAATGAAGTGCTGATGAAGCGGAGCAGCGACAGATTCGTGCCTCTGCTGC  TGCAGTATATCGATTACGGCAAGCTGTTCGACCACATCAGGTTCCACGTGAACATGGGCAAGCT  GAGATACCTGCTGAAGGCCGACAAGACCTGCATCGACGGCCAGACCAGAGTCAGAGTGATCGAG  CAGCCCCTGAACGGCTTCGGCAGACTGGAAGAGGCCGAGACAATGCGGAAGCAAGAGAACGGCA  CCTTCGGCAACAGCGGCATCCGGATCAGAGACTTCGAGAACATGAAGCGGGACGACGCCAATCC  TGCCAACTATCCCTACATCGTGGACACCTACACACACTACATCCTGGAAAACAACAAGGTCGAG  ATGTTTATCAACGACAAAGAGGACAGCGCCCCACTGCTGCCCGTGATCGAGGATGATAGATACG  TGGTCAAGACAATCCCCAGCTGCCGGATGAGCACCCTGGAAATTCCAGCCATGGCCTTCCACAT  GTTTCTGTTCGGCAGCAAGAAAACCGAGAAGCTGATCGTGGACGTGCACAACCGGTACAAGAGA  CTGTTCCAGGCCATGCAGAAAGAAGAAGTGACCGCCGAGAATATCGCCAGCTTCGGAATCGCCG  AGAGCGACCTGCCTCAGAAGATCCTGGATCTGATCAGCGGCAATGCCCACGGCAAGGATGTGGA  CGCCTTCATCAGACTGACCGTGGACGACATGCTGACCGACACCGAGCGGAGAATCAAGAGATTC  AAGGACGACCGGAAGTCCATTCGGAGCGCCGACAACAAGATGGGAAAGAGAGGCTTCAAGCAGA  TCTCCACAGGCAAGCTGGCCGACTTCCTGGCCAAGGACATCGTGCTGTTTCAGCCCAGCGTGAA  CGATGGCGAGAACAAGATCACCGGCCTGAACTACCGGATCATGCAGAGCGCCATTGCCGTGTAC  GATAGCGGCGACGATTACGAGGCCAAGCAGCAGTTCAAGCTGATGTTCGAGAAGGCCCGGCTGA  TCGGCAAGGGCACAACAGAGCCTCATCCATTTCTGTACAAGGTGTTCGCCCGCAGCATCCCCGC  CAATGCCGTCGAGTTCTACGAGCGCTACCTGATCGAGCGGAAGTTCTACCTGACCGGCCTGTCC  AACGAGATCAAGAAAGGCAACAGAGTGGATGTGCCCTTCATCCGGCGGGACCAGAACAAGTGGA  AAACACCCGCCATGAAGACCCTGGGCAGAATCTACAGCGAGGATCTGCCCGTGGAACTGCCCAG  ACAGATGTTCGACAATGAGATCAAGTCCCACCTGAAGTCCCTGCCACAGATGGAAGGCATCGAC  TTCAACAATGCCAACGTGACCTATCTGATCGCCGAGTACATGAAGAGAGTGCTGGACGACGACT  TCCAGACCTTCTACCAGTGGAACCGCAACTACCGGTACATGGACATGCTTAAGGGCGAGTACGA  CAGAAAGGGCTCCCTGCAGCACTGCTTCACCAGCGTGGAAGAGAGAGAAGGCCTCTGGAAAGAG  CGGGCCTCCAGAACAGAGCGGTACAGAAAGCAGGCCAGCAACAAGATCCGCAGCAACCGGCAGA  TGAGAAACGCCAGCAGCGAAGAGATCGAGACAATCCTGGATAAGCGGCTGAGCAACAGCCGGAA  CGAGTACCAGAAAAGCGAGAAAGTGATCCGGCGCTACAGAGTGCAGGATGCCCTGCTGTTTCTG  CTGGCCAAAAAGACCCTGACCGAACTGGCCGATTTCGACGGCGAGAGGTTCAAACTGAAAGAAA  TCATGCCCGACGCCGAGAAGGGAATCCTGAGCGAGATCATGCCCATGAGCTTCACCTTCGAGAA  AGGCGGCAAGAAGTACACCATCACCAGCGAGGGCATGAAGCTGAAGAACTACGGCGACTTCTTT  GTGCTGGCTAGCGACAAGAGGATCGGCAACCTGCTGGAACTCGTGGGCAGCGACATCGTGTCCA  AAGAGGATATCATGGAAGAGTTCAACAAATACGACCAGTGCAGGCCCGAGATCAGCTCCATCGT  GTTCAACCTGGAAAAGTGGGCCTTCGACACATACCCCGAGCTGTCTGCCAGAGTGGACCGGGAA  GAGAAGGTGGACTTCAAGAGCATCCTGAAAATCCTGCTGAACAACAAGAACATCAACAAAGAGC  AGAGCGACATCCTGCGGAAGATCCGGAACGCCTTCGATCACAACAATTACCCCGACAAAGGCGT  GGTGGAAATCAAGGCCCTGCCTGAGATCGCCATGAGCATCAAGAAGGCCTTTGGGGAGTACGCC  ATCATGAAGTAGTAA   3xFLAG-Ty1NLS-PspCas13b  MDYKDHDGDYKDHDIDYKDDDDKGGNSKKRSLEDNETEIKVSRDTWNTKNMRSLEPPRSKKRIH  GGNIPALVENQKKYFGTYSVMAMLNAQTVLDHIQKVADIEGEQNENNENLWFHPVMSHLYNAKN  GYDKQPEKTMFIIERLQSYFPFLKIMAENQREYSNGKYKQNRVEVNSNDIFEVLKRAFGVLKMY  RDLTNHYKTYEEKLNDGCEFLTSTEQPLSGMINNYYTVALRNMNERYGYKTEDLAFIQDKRFKF  VKDAYGKKKSQVNTGFFLSLQDYNGDTQKKLHLSGVGIALLICLFLDKQYINIFLSRLPIFSSY  NAQSEERRIIIRSFGINSIKLPKDRIHSEKSNKSVAMDMLNEVKRCPDELFTTLSAEKQSRFRI  ISDDHNEVLMKRSSDRFVPLLLQYIDYGKLFDHIRFHVNMGKLRYLLKADKTCIDGQTRVRVIE  QPLNGFGRLEEAETMRKQENGTFGNSGIRIRDFENMKRDDANPANYPYIVDTYTHYILENNKVE  MFINDKEDSAPLLPVIEDDRYVVKTIPSCRMSTLEIPAMAFHMFLFGSKKTEKLIVDVHNRYKR  LFQAMQKEEVTAENIASFGIAESDLPQKILDLISGNAHGKDVDAFIRLTVDDMLTDTERRIKRF  KDDRKSIRSADNKMGKRGFKQISTGKLADFLAKDIVLFQPSVNDGENKITGLNYRIMQSAIAVY  DSGDDYEAKQQFKLMFEKARLIGKGTTEPHPFLYKVFARSIPANAVEFYERYLIERKFYLTGLS  NEIKKGNRVDVPFIRRDQNKWKTPAMKTLGRIYSEDLPVELPRQMFDNEIKSHLKSLPQMEGID  FNNANVTYLIAEYMKRVLDDDFQTFYQWNRNYRYMDMLKGEYDRKGSLQHCFTSVEEREGLWKE  RASRTERYRKQASNKIRSNRQMRNASSEEIETILDKRLSNSRNEYQKSEKVIRRYRVQDALLFL  LAKKTLTELADFDGERFKLKEIMPDAEKGILSEIMPMSFTFEKGGKKYTITSEGMKLKNYGDFF  VLASDKRIGNLLELVGSDIVSKEDIMEEFNKYDQCRPEISSIVFNLEKWAFDTYPELSARVDRE  EKVDFKSILKILLNNKNINKEQSDILRKIRNAFDHNNYPDKGVVEIKALPEIAMSIKKAFGEYA  IMK** 
